BMRN : Analysis & Opinions

  1. Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - ...

    January 28, 2015
    Synageva BioPharma Corp. (GEVA) has commenced patient dosing in a phase I/II study on SBC-103 for mucopolysaccharidosis IIIB ...
  2. BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst ...

    January 22, 2015
    BioMarin (BMRN) will be raising approximately $792.6 million through the issuance of the shares in order to finance the Prosensa ...
  3. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
  4. BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst ...

    January 14, 2015
    BioMarin (BMRN) raised its 2014 guidance for Vimizim sales and presented encouraging interim data from an ongoing phase I/II ...
  5. BioMarin Pharmaceutical Inc. (BMRN): New Analyst Report from ...

    January 5, 2015
    BioMarin's third-quarter 2014 loss of $0.16 per share was narrower than the Zacks Consensus Estimate of a loss of $0.22. ...
  6. BioMarin's Vimizim OK'd in Japan for Morquio A Syndrome - Analyst ...

    December 30, 2014
    BioMarin's (BMRN) Vimizim gained Japanese approval for the treatment of patients suffering from mucopolysaccharidosis type ...
  7. 4 Biotech Stocks that Doubled in 2014 - Analyst Blog

    December 26, 2014
    Promising pipeline candidates, progress on the regulatory front and interesting research platforms helped these 4 biotech ...
  8. 4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst ...

    December 16, 2014
    Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, ...
  9. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  10. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  11. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  12. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  13. Betting On Healthcare's Growth Engine

    August 17, 2011
    In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
Trading Center